Breaking News Instant updates and real-time market news.

2022-06-27 06:51:04 GCO Genesco $56.64 / +2.46 (+4.54%) 06:51 06/27/22 06/27 06:51 06/27/22 06:51	Genesco appoints Gregory Sandfort as lead independent director Genesco Inc. announced that the independent directors of the Genesco Board have unanimously selected Gregory A. Sandfort as the company's Lead Independent Director, effective June 23, 2022. Sandfort succeeds Matthew C. Diamond who has served in that role for the past four years. Sandfort, who joined Genesco's Board in 2021, will continue to serve on Genesco's Audit and Compensation committees. Diamond will remain on the Genesco Board. "We are pleased to announce Greg's appointment as our next lead independent director," said Mimi E. Vaughn, Genesco's Board Chair, President and CEO. "He brings more than 40 years of strategic retail leadership to our Board with a deep understanding of customer dynamics, the ability to successfully lead business transformations, along with expertise in capital allocation. I look forward to working with Greg as we continue to build on Genesco's footwear focused strategy."

2022-06-27 06:51:04

GCO

Genesco

$56.64 / +2.46 (+4.54%)

06:51

06/27/22

06/27

06:51

06/27/22

06:51

Genesco appoints Gregory Sandfort as lead independent director

Genesco Inc. announced that the independent directors of the Genesco Board have unanimously selected Gregory A. Sandfort as the company's Lead Independent Director, effective June 23, 2022. Sandfort succeeds Matthew C. Diamond who has served in that role for the past four years. Sandfort, who joined Genesco's Board in 2021, will continue to serve on Genesco's Audit and Compensation committees. Diamond will remain on the Genesco Board. "We are pleased to announce Greg's appointment as our next lead independent director," said Mimi E. Vaughn, Genesco's Board Chair, President and CEO. "He brings more than 40 years of strategic retail leadership to our Board with a deep understanding of customer dynamics, the ability to successfully lead business transformations, along with expertise in capital allocation. I look forward to working with Greg as we continue to build on Genesco's footwear focused strategy."

OTHER BREAKING NEWS FROM THE FLY

Downgrade	Landos Biopharma downgraded to Market Perform from Outperform at Raymond James » 05:51 08/12/22 08/12 05:51 08/12/22 05:51 LABP Landos Biopharma $1.09 / -0.13 (-10.66%) Raymond James analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings LABP Landos Biopharma $1.09 / -0.13 (-10.66%) 08/11/22 Landos Biopharma expects cash to fund operations for at least next 12 months 08/03/22 Landos Biopharma announces top-line results from NX-13 Phase 1b trial 06/21/22 Landos Biopharma appoints Gregory Oakes as president, CEO 03/10/22 Landos Biopharma appoints Roger Adsett to board of directors LABP Landos Biopharma $1.09 / -0.13 (-10.66%) 04/12/22 Jefferies Jefferies downgrades Landos Biopharma, slashes target on 'uncertain' pipeline 04/12/22 Jefferies Landos Biopharma downgraded to Hold from Buy at Jefferies 03/25/22 Raymond James Landos Biopharma price target lowered to $9 from $24 at Raymond James 11/18/21 Craig-Hallum Landos Biopharma price target lowered to $29.50 from $45 at Craig-Hallum LABP Landos Biopharma $1.09 / -0.13 (-10.66%) 08/11/22 Landos Biopharma reports Q2 EPS (28c), consensus (33c) 03/24/22 Landos Biopharma reports FY21 EPS ($1.02), consensus (88c)
Initiation	Lexicon initiated with an Overweight at Piper Sandler » 05:50 08/12/22 08/12 05:50 08/12/22 05:50 LXRX Lexicon $2.75 / -0.03 (-1.08%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings LXRX Lexicon $2.75 / -0.03 (-1.08%) 08/02/22 Lexicon reports Q2 EPS (16c), consensus (16c) 07/27/22 Lexicon announces FDA acceptance of NDA for sotagliflozin 06/29/22 Lexicon Pharmaceuticals trading resumes 06/29/22 Lexicon proof-of-concept study of LX9211 achieves primary endpoint LXRX Lexicon $2.75 / -0.03 (-1.08%) 07/01/22 Citi Citi disagrees with Lexicon selloff yesterday, ups target to $20 03/01/22 Citi Lexicon selloff on filing delay a buying opportunity, says Citi 08/30/21 Citi Lexicon price target raised to $20 from $13 at Citi LXRX Lexicon $2.75 / -0.03 (-1.08%) 05/05/22 Lexicon reports Q1 EPS (16c), consensus (16c) 02/28/22 Lexicon reports Q4 EPS (17c), consensus (18c)
Downgrade	Olo downgraded to Neutral from Overweight at Piper Sandler » 05:47 08/12/22 08/12 05:47 08/12/22 05:47 OLO Olo $13.00 / -0.235 (-1.78%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly OLO Olo $13.00 / -0.235 (-1.78%) 05/10/22 Olo appoints Diego Panama as chief revenue officer 04/14/22 Olo, SOCi partner for SOCi integration with Olo API 03/04/22 Olo announces integration with Radar 02/23/22 Olo launches Olo Pay OLO Olo $13.00 / -0.235 (-1.78%) 05:26 Today Stifel Olo downgraded to Hold from Buy at Stifel 07/18/22 Piper Sandler Olo price target lowered to $13 from $14 at Piper Sandler 06/17/22 JPMorgan Olo price target lowered to $21 from $26 at JPMorgan 02/24/22 Truist Olo price target lowered to $25 from $45 at Truist OLO Olo $13.00 / -0.235 (-1.78%) 08/11/22 Olo cuts FY22 revenue view to $183M-$184M, consensus $195.6M 08/11/22 Olo sees Q3 revenue $46.5M-$47.0M, consensus $51.1M 08/11/22 Olo reports Q2 EPS 1c, consensus 0c 05/10/22 Olo sees Q2 revenue $45.5M-$46M, consensus $45.48M OLO Olo $13.00 / -0.235 (-1.78%) 08/11/22 Fly Intel: After-Hours Movers
Periodicals	Samsung heir Jay Y. Lee to receive presidential pardon, Bloomberg reports » 05:46 08/12/22 08/12 05:46 08/12/22 05:46 SSNLF Samsung $57.75 / + (+0.00%) Samsung heir Jay Y. Lee… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly SSNLF Samsung $57.75 / + (+0.00%) 07/28/22 Samsung Display segment Q2 earnings 'solid despite weak seasonality' 07/27/22 Qualcomm, Samsung extend, expand strategic partnership 06/30/22 Samsung begins chip production using 3nm process technology 06/09/22 Microsoft, Samsung partner to bring Xbox Cloud Gaming to Samsung Smart TVs SSNLF Samsung $57.75 / + (+0.00%) 08/11/22 Loop Capital Loop Capital has 'stronger conviction' in Enovix after 'customer milestones' 06/22/22 Loop Capital Samsung initiated with a Buy at Loop Capital 06/13/22 KeyBanc Qualcomm price target raised to $220 from $200 at KeyBanc 06/13/22 UBS Micron price target lowered to $115 from $120 at UBS SSNLF Samsung $57.75 / + (+0.00%) 07/28/22 Samsung reports Q2 EPS KRW 1,613 vs. KRW 1,391 last year 07/06/22 Samsung sees Q2 operating profit KRW14.0T vs. KRW14.6T consensus 04/28/22 Samsung reports Q1 EPS KRW 1,638 vs. KRW 1,044 last year 04/06/22 Samsung sees Q1 operating profit KRW14.1T vs. KRW13.4T consensus SSNLF Samsung $57.75 / + (+0.00%) 08/09/22 Samsung plans $3.3B investment in Vietnam, South China Morning Post reports 08/03/22 Samsung rethinking China exposure amid Chips and Science Act, FT reports 07/21/22 Samsung considering building 11 chipmaking facility, American-Statesman reports 07/18/22 Samsung may hold latest foldable launch event on August 10, Verge says SSNLF Samsung $57.75 / + (+0.00%) 07/21/22 What You Missed On Wall Street On Thursday 07/21/22 What You Missed On Wall Street This Morning 07/06/22 What You Missed This Week in Video Games 06/14/22 What You Missed This Week in Video Games
Downgrade	Six Flags downgraded to Sector Weight at KeyBanc after 'indefensible' Q2 » 05:44 08/12/22 08/12 05:44 08/12/22 05:44 SIX Six Flags $21.12 / -4.685 (-18.16%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 Six Flags falls -22.5% 08/11/22 Six Flags falls -21.5% 08/11/22 Six Flags falls -18.1% 08/11/22 Six Flags reports Q2 attendance 6.7M vs. 8.5M a year ago, down 22% SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 KeyBanc Six Flags downgraded to Sector Weight from Overweight at KeyBanc 07/08/22 Citi Six Flags downgraded to Neutral from Buy at Citi 06/24/22 Stifel Six Flags price target lowered to $35 from $52 at Stifel 06/21/22 B. Riley Six Flags downgraded to Neutral from Buy at B. Riley SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 Six Flags reports Q2 EPS 53c, consensus $1.02 08/10/22 Notable companies reporting before tomorrow's open 08/10/22 Notable companies reporting before tomorrow's open 05/12/22 Six Flags reports Q1 EPS (76c), consensus ($1.04) SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 What You Missed On Wall Street This Morning 08/11/22 Fly Intel: Pre-market Movers 07/21/22 Fly Intel: After-Hours Movers
Downgrade	Cowen cuts CS Disco to Market Perform as momentum hits 'big snag' » 05:40 08/12/22 08/12 05:40 08/12/22 05:40 LAW CS Disco $28.96 / +0.39 (+1.37%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly LAW CS Disco $28.96 / +0.39 (+1.37%) 06/06/22 DISCO appoints Tom Furr as CMO 06/01/22 CS Disco falls -10.8% 04/28/22 DISCO appoints Jignasha Amin Grooms as CHRO LAW CS Disco $28.96 / +0.39 (+1.37%) 05:35 Today Cowen CS Disco downgraded to Market Perform from Outperform at Cowen 05:22 Today Jefferies CS Disco downgraded to Hold from Buy at Jefferies 05/23/22 Jefferies CS Disco price target lowered to $35 from $40 at Jefferies 05/13/22 Needham CS Disco price target lowered to $35 from $50 at Needham LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 CS Disco cuts FY22 revenue view to $132M-$136M from $149M-$153M 08/11/22 CS Disco sees Q3 revenue $32M-$34M, consensus $38.29M 08/11/22 CS Disco reports Q2 adjusted (23c), consensus (27c) 05/12/22 CS Disco sees Q2 revenue $32M-$34M, consensus $34.02M 15 Sep LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 Fly Intel: After-Hours Movers 05/12/22 Fly Intel: After-Hours Movers
Downgrade	RealReal downgraded to Market Perform from Outperform at Cowen » 05:38 08/12/22 08/12 05:38 08/12/22 05:38 REAL RealReal $3.16 / +0.065 (+2.10%) Cowen analyst Oliver Chen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options REAL RealReal $3.16 / +0.065 (+2.10%) 07/27/22 RealReal enters partnership with Beckett Collectibles 06/07/22 RealReal announces Founder Julie Wainwright to stepdown from CEO role 04/29/22 RealReal announces expansion of Sustainability Calculator 03/22/22 RealReal provides long-range financial targets for FY25 REAL RealReal $3.16 / +0.065 (+2.10%) 08/10/22 Wells Fargo RealReal price target lowered to $8 from $15 at Wells Fargo 08/10/22 Needham RealReal price target lowered to $6 from $10 at Needham 08/10/22 Wedbush RealReal price target lowered to $5 from $10 at Wedbush 08/10/22 BofA RealReal double downgraded to Underperform at BofA REAL RealReal $3.16 / +0.065 (+2.10%) 08/09/22 RealReal sees Q3 revenue $145M-$155M, consensus $164.08M 08/09/22 RealReal sees FY22 revenue $615M-$635M, consensus $652.44M 08/09/22 RealReal reports Q2 adjusted EPS (40c), consensus (43c) 08/09/22 Notable companies reporting after market close REAL RealReal $3.16 / +0.065 (+2.10%) 08/10/22 What You Missed On Wall Street On Wednesday 08/10/22 What You Missed On Wall Street This Morning 08/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/09/22 Fly Intel: After-Hours Movers REAL RealReal $3.16 / +0.065 (+2.10%) 08/09/22 RealReal options imply 16.1% move in share price post-earnings 02/23/22 RealReal options imply 16.4% move in share price post-earnings
Downgrade	e.l.f. Beauty downgraded to Market Perform from Outperform at Cowen » 05:38 08/12/22 08/12 05:38 08/12/22 05:38 ELF e.l.f. Beauty $36.44 / -0.02 (-0.05%) Cowen analyst Oliver Chen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events ELF e.l.f. Beauty $36.44 / -0.02 (-0.05%) 07/05/22 Chairman of e.l.f. Beauty Tarang Amin sells $1.3M in company shares 06/07/22 e.l.f. Beauty CEO: We continue to take market share ELF e.l.f. Beauty $36.44 / -0.02 (-0.05%) 08/04/22 Truist e.l.f. Beauty price target raised to $40 from $35 at Truist 07/21/22 JPMorgan e.l.f. Beauty price target raised to $35 from $30 at JPMorgan 05/26/22 Raymond James e.l.f. Beauty price target lowered to $27 from $33 at Raymond James 05/26/22 Morgan Stanley e.l.f. Beauty sounded 'very bullish' on earnings call, says Morgan Stanley ELF e.l.f. Beauty $36.44 / -0.02 (-0.05%) 08/03/22 e.l.f. Beauty raises FY23 EPSE view to 84c-87c from 78c-81c 08/03/22 e.l.f. Beauty reports Q1 EPS 39c, consensus 23c 05/25/22 e.l.f. Beauty sees FY23 adjusted EPS 78c-81c, consensus 84c 05/25/22 e.l.f. Beauty reports Q4 adjusted EPS 13c, consensus 6c ELF e.l.f. Beauty $36.44 / -0.02 (-0.05%) 07/11/22 Fly Insider: Karuna Therapeutics, HP among weeks notable insider trades 05/25/22 Fly Intel: After-Hours Movers 04/06/22 What You Missed On Wall Street On Wednesday 04/06/22 What You Missed On Wall Street This Morning 11/02/22 e.l.f. Beauty - ELF 08/25/22 E.L.F. BEAUTY 09/13/22 e.l.f. Beauty 09/14/22 e.l.f. Beauty
Upgrade	Ciena upgraded to Overweight at Morgan Stanley as supply chain improves » 05:36 08/12/22 08/12 05:36 08/12/22 05:36 CIEN Ciena $52.90 / -1.08 (-2.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CIEN Ciena $52.90 / -1.08 (-2.00%) 06/02/22 Ciena falls -8.3% 06/02/22 Ciena sees Q3 OpEx $305M-$310M 06/02/22 Ciena CEO: Long-term secular drivers creating 'incredible' demand environment 06/02/22 Ciena CEO: Supply chain conditions worsened throughout quarter, says CEO CIEN Ciena $52.90 / -1.08 (-2.00%) 05:30 Today Morgan Stanley Ciena upgraded to Overweight from Equal Weight at Morgan Stanley 08/04/22 MKM Partners Ciena assumed with a Buy at MKM Partners 07/14/22 JPMorgan Ciena price target lowered to $62 from $72 at JPMorgan 07/14/22 JPMorgan JPMorgan adds Qualcomm to Analyst Focus List, removes Ciena CIEN Ciena $52.90 / -1.08 (-2.00%) 06/02/22 Ciena sees FY revenue growth in mid single digits, consensus $4.06B 06/02/22 Ciena sees Q3 revenue $870M-$930M, consensus $1.08B 06/02/22 Ciena reports Q2 adjusted EPS 50c, consensus 54c 06/01/22 Notable companies reporting before tomorrow's open CIEN Ciena $52.90 / -1.08 (-2.00%) 06/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/02/22 What You Missed On Wall Street On Thursday 06/02/22 What You Missed On Wall Street This Morning 06/02/22 Fly Intel: Pre-market Movers
Downgrade	Centessa double downgraded to Underweight from Overweight at Morgan Stanley » 05:36 08/12/22 08/12 05:36 08/12/22 05:36 CNTA Centessa $4.27 / -0.43 (-9.15%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options CNTA Centessa $4.27 / -0.43 (-9.15%) 08/10/22 Centessa to discontinue development of ZF874 07/25/22 Centessa appoints Rotmas as SVP, Regulatory Affairs 07/18/22 Evelo Biosciences names Marella Thorell as CFO, effective September 1 07/01/22 Centessa appoints Mathias Hukkelhoven to board of directors CNTA Centessa $4.27 / -0.43 (-9.15%) 05:29 Today Morgan Stanley Centessa downgraded to Underweight from Overweight at Morgan Stanley 08/11/22 BMO Capital Centessa price target lowered to $11 from $19 at BMO Capital 06/16/22 BMO Capital Centessa initiated with an Outperform at BMO Capital 06/03/22 Jefferies Centessa downgraded to Hold from Buy at Jefferies CNTA Centessa $4.27 / -0.43 (-9.15%) 08/10/22 Centessa reports Q2 EPS (69c) vs. (65c) a year ago 05/16/22 Centessa reports Q1 EPS (60c), consensus (70c) 03/30/22 Centessa reports Q4 EPS (68c), consensus (60c) CNTA Centessa $4.27 / -0.43 (-9.15%) 07/07/22 Eighteen new option listings and one option delisting on July 7th

Downgrade	CS Disco downgraded to Market Perform from Outperform at Cowen » 05:35 08/12/22 08/12 05:35 08/12/22 05:35 LAW CS Disco $28.96 / +0.39 (+1.37%) Cowen analyst J. Derrick… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly LAW CS Disco $28.96 / +0.39 (+1.37%) 06/06/22 DISCO appoints Tom Furr as CMO 06/01/22 CS Disco falls -10.8% 04/28/22 DISCO appoints Jignasha Amin Grooms as CHRO LAW CS Disco $28.96 / +0.39 (+1.37%) 05:22 Today Jefferies CS Disco downgraded to Hold from Buy at Jefferies 05/23/22 Jefferies CS Disco price target lowered to $35 from $40 at Jefferies 05/13/22 Needham CS Disco price target lowered to $35 from $50 at Needham 05/13/22 Cowen CS Disco price target lowered to $35 from $45 at Cowen LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 CS Disco cuts FY22 revenue view to $132M-$136M from $149M-$153M 08/11/22 CS Disco sees Q3 revenue $32M-$34M, consensus $38.29M 08/11/22 CS Disco reports Q2 adjusted (23c), consensus (27c) 05/12/22 CS Disco sees Q2 revenue $32M-$34M, consensus $34.02M 15 Sep LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 Fly Intel: After-Hours Movers 05/12/22 Fly Intel: After-Hours Movers
General news	Energy Action: » 05:35 08/12/22 08/12 05:35 08/12/22 05:35 $ECON Economic Data / + Energy Action: Oil prices… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly $ECON Economic Data / + 06/22/22 President Biden calls on Congress to suspend federal gas tax 05/19/22 Could crypto crash be good for U.S. economy? Probably. 05/12/22 Miller calls out Taylor Morrison, GM as names that may work in this environment 04/21/22 Powell says 50 basis point hike on table for May meeting $ECON Economic Data / + $ECON Economic Data / + 06/14/22 Ackman says 100 point hike tomorrow 'would be better' than 75 $ECON Economic Data / + 07/26/22 Ackman says biggest risk to economy is inflation, not higher rates 06/17/22 White House, Congress in talks over bill to fight inflation, Bloomberg says 06/13/22 Fed more likely to consider 0.75 point hike given recent data, WSJ says 05/10/22 Tepper says covered Nasdaq short, CNBC reports $ECON Economic Data / + 07/27/22 What You Missed On Wall Street On Wednesday 07/21/22 What You Missed On Wall Street On Thursday 07/21/22 What You Missed On Wall Street This Morning 07/06/22 What You Missed On Wall Street On Wednesday
Upgrade	Sanofi upgraded to Hold from Sell at Deutsche Bank » 05:33 08/12/22 08/12 05:33 08/12/22 05:33 SNY Sanofi $43.46 / -1.74 (-3.85%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 Sanofi says 'confident in its legal defenses' related to U.S. Zantac litigation 08/04/22 Sanofi announces strategic collaboration with Innovent Biologics 07/21/22 Innate Pharma announces Sanofi decision to progress IPH6401/SAR'514 07/18/22 Editas Medicine appoints Mei as SVP, CMO SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 JPMorgan Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan 08/11/22 Deutsche Bank Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank 08/09/22 UBS Sanofi downgraded to Neutral from Buy at UBS 08/05/22 Stifel Sanofi price target raised to EUR 119 from EUR 115 at Stifel SNY Sanofi $43.46 / -1.74 (-3.85%) 07/28/22 Sanofi sees 2022 business EPS growing 15% at CER 07/28/22 Sanofi reports Q2 business EPS EUR 1.73, up 16.7% at CER 04/28/22 Sanofi still expects 2022 business EPS to grow low double-digit at CER 04/28/22 Sanofi reports Q1 business EPS EUR 1.94, up 16.1% at CER SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 GSK, Sanofi weakness related to Zantac litigation worries, Bloomberg reports SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 Renewed Zantac litigation concerns sinking these big-cap drugmakers 08/11/22 What You Missed On Wall Street This Morning 06/24/22 What You Missed On Wall Street On Friday 09/10/22 ESMO Congress 2022
Upgrade	Ciena upgraded to Overweight from Equal Weight at Morgan Stanley » 05:30 08/12/22 08/12 05:30 08/12/22 05:30 CIEN Ciena $52.90 / -1.08 (-2.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CIEN Ciena $52.90 / -1.08 (-2.00%) 06/02/22 Ciena falls -8.3% 06/02/22 Ciena sees Q3 OpEx $305M-$310M 06/02/22 Ciena CEO: Long-term secular drivers creating 'incredible' demand environment 06/02/22 Ciena CEO: Supply chain conditions worsened throughout quarter, says CEO CIEN Ciena $52.90 / -1.08 (-2.00%) 08/04/22 MKM Partners Ciena assumed with a Buy at MKM Partners 07/14/22 JPMorgan Ciena price target lowered to $62 from $72 at JPMorgan 07/14/22 JPMorgan JPMorgan adds Qualcomm to Analyst Focus List, removes Ciena 07/12/22 Rosenblatt Juniper initiated with a Neutral at Rosenblatt CIEN Ciena $52.90 / -1.08 (-2.00%) 06/02/22 Ciena sees FY revenue growth in mid single digits, consensus $4.06B 06/02/22 Ciena sees Q3 revenue $870M-$930M, consensus $1.08B 06/02/22 Ciena reports Q2 adjusted EPS 50c, consensus 54c 06/01/22 Notable companies reporting before tomorrow's open CIEN Ciena $52.90 / -1.08 (-2.00%) 06/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/02/22 What You Missed On Wall Street On Thursday 06/02/22 What You Missed On Wall Street This Morning 06/02/22 Fly Intel: Pre-market Movers
Downgrade	Centessa downgraded to Underweight from Overweight at Morgan Stanley » 05:29 08/12/22 08/12 05:29 08/12/22 05:29 CNTA Centessa $4.27 / -0.43 (-9.15%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options CNTA Centessa $4.27 / -0.43 (-9.15%) 08/10/22 Centessa to discontinue development of ZF874 07/25/22 Centessa appoints Rotmas as SVP, Regulatory Affairs 07/18/22 Evelo Biosciences names Marella Thorell as CFO, effective September 1 07/01/22 Centessa appoints Mathias Hukkelhoven to board of directors CNTA Centessa $4.27 / -0.43 (-9.15%) 08/11/22 BMO Capital Centessa price target lowered to $11 from $19 at BMO Capital 06/16/22 BMO Capital Centessa initiated with an Outperform at BMO Capital 06/03/22 Jefferies Centessa downgraded to Hold from Buy at Jefferies 02/11/22 Goldman Sachs Centessa assumed with a Neutral at Goldman Sachs CNTA Centessa $4.27 / -0.43 (-9.15%) 08/10/22 Centessa reports Q2 EPS (69c) vs. (65c) a year ago 05/16/22 Centessa reports Q1 EPS (60c), consensus (70c) 03/30/22 Centessa reports Q4 EPS (68c), consensus (60c) CNTA Centessa $4.27 / -0.43 (-9.15%) 07/07/22 Eighteen new option listings and one option delisting on July 7th
Downgrade	II-VI downgraded to Equal Weight from Overweight at Morgan Stanley » 05:28 08/12/22 08/12 05:28 08/12/22 05:28 IIVI II-VI $52.52 / +0.38 (+0.73%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events IIVI II-VI $52.52 / +0.38 (+0.73%) 07/18/22 II-VI, Artilux demonstrate a 3D camera for the metaverse 07/11/22 BCPE Watson reports 12.3% stake in II-VI, plans active role 07/05/22 Omnicell to replace Coherent in S&P 400 at open on 7/5 07/01/22 II-VI completes acquisition of Coherent IIVI II-VI $52.52 / +0.38 (+0.73%) 07/25/22 Barclays II-VI price target lowered to $47 from $65 at Barclays 07/01/22 Craig-Hallum II-VI price target lowered to $80 from $85 at Craig-Hallum 05/17/22 Piper Sandler Piper moves to 'more positive stance' on semiconductor stocks 05/10/22 Raymond James II-VI price target raised to $82 from $79 at Raymond James IIVI II-VI $52.52 / +0.38 (+0.73%) 05/10/22 II-VI sees Q4 adjusted EPS 85c-$1.00, consensus 92c 05/10/22 II-VI reports Q3 adjusted EPS 95c, consensus 85c 05/09/22 Notable companies reporting before tomorrow's open 05/09/22 Notable companies reporting before tomorrow's open IIVI II-VI $52.52 / +0.38 (+0.73%) 06/23/22 China to conditionally clear II-VI deal to buy Coherent, Dealreporter says 05/18/22 II-VI, Coherent see uncertainty added to SAMR deal reviews, Capitol Forum says IIVI II-VI $52.52 / +0.38 (+0.73%) 06/28/22 What You Missed On Wall Street On Tuesday 06/28/22 What You Missed On Wall Street This Morning 05/18/22 What You Missed On Wall Street On Wednesday 05/18/22 What You Missed On Wall Street This Morning 08/24/22 II-VI - IIVI
Downgrade	Olo downgraded to Hold from Buy at Stifel » 05:26 08/12/22 08/12 05:26 08/12/22 05:26 OLO Olo $13.00 / -0.235 (-1.78%) Stifel analyst Brad… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly OLO Olo $13.00 / -0.235 (-1.78%) 05/10/22 Olo appoints Diego Panama as chief revenue officer 04/14/22 Olo, SOCi partner for SOCi integration with Olo API 03/04/22 Olo announces integration with Radar 02/23/22 Olo launches Olo Pay OLO Olo $13.00 / -0.235 (-1.78%) 07/18/22 Piper Sandler Olo price target lowered to $13 from $14 at Piper Sandler 06/17/22 JPMorgan Olo price target lowered to $21 from $26 at JPMorgan 02/24/22 Truist Olo price target lowered to $25 from $45 at Truist 02/24/22 Piper Sandler Olo price target lowered to $20 from $33 at Piper Sandler OLO Olo $13.00 / -0.235 (-1.78%) 08/11/22 Olo cuts FY22 revenue view to $183M-$184M, consensus $195.6M 08/11/22 Olo sees Q3 revenue $46.5M-$47.0M, consensus $51.1M 08/11/22 Olo reports Q2 EPS 1c, consensus 0c 05/10/22 Olo sees Q2 revenue $45.5M-$46M, consensus $45.48M OLO Olo $13.00 / -0.235 (-1.78%) 08/11/22 Fly Intel: After-Hours Movers
Downgrade	CS Disco downgraded to Hold from Buy at Jefferies » 05:22 08/12/22 08/12 05:22 08/12/22 05:22 LAW CS Disco $28.96 / +0.39 (+1.37%) Jefferies analyst Brent… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly LAW CS Disco $28.96 / +0.39 (+1.37%) 06/06/22 DISCO appoints Tom Furr as CMO 06/01/22 CS Disco falls -10.8% 04/28/22 DISCO appoints Jignasha Amin Grooms as CHRO LAW CS Disco $28.96 / +0.39 (+1.37%) 05/23/22 Jefferies CS Disco price target lowered to $35 from $40 at Jefferies 05/13/22 Needham CS Disco price target lowered to $35 from $50 at Needham 05/13/22 Cowen CS Disco price target lowered to $35 from $45 at Cowen 05/13/22 Canaccord CS Disco price target lowered to $35 from $45 at Canaccord LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 CS Disco cuts FY22 revenue view to $132M-$136M from $149M-$153M 08/11/22 CS Disco sees Q3 revenue $32M-$34M, consensus $38.29M 08/11/22 CS Disco reports Q2 adjusted (23c), consensus (27c) 05/12/22 CS Disco sees Q2 revenue $32M-$34M, consensus $34.02M 15 Sep LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 Fly Intel: After-Hours Movers 05/12/22 Fly Intel: After-Hours Movers
Downgrade	Eutelsat downgraded to Underweight from Neutral at JPMorgan » 05:19 08/12/22 08/12 05:19 08/12/22 05:19 ETCMY Eutelsat $2.27 / + (+0.00%) JPMorgan analyst Akhil… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research ETCMY Eutelsat $2.27 / + (+0.00%) 07/27/22 Deutsche Bank Eutelsat price target lowered to EUR 10 from EUR 13 at Deutsche Bank 07/27/22 Deutsche Bank Eutelsat downgraded to Hold from Buy at Deutsche Bank 07/26/22 Kepler Cheuvreux Eutelsat downgraded to Hold from Buy at Kepler Cheuvreux 07/13/22 Barclays Eutelsat price target raised to EUR 12.65 from EUR 12 at Barclays
Downgrade	Television Francaise 1 downgraded to Underweight from Overweight at Barclays » 05:16 08/12/22 08/12 05:16 08/12/22 05:16 TVFCF Television Francaise 1 $8.87 / + (+0.00%) Barclays analyst Julien… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research TVFCF Television Francaise 1 $8.87 / + (+0.00%) 07/20/22 UBS Television Francaise 1 price target lowered to EUR 7.20 from EUR 9.80 at UBS 02/15/22 Barclays Television Francaise 1 price target raised to EUR 13 from EUR 12.25 at Barclays 12/10/21 Barclays Television Francaise price target lowered to EUR 10.50 from EUR 11 at Barclays 11/01/21 Barclays Television Francaise 1 price target raised to EUR 11 from EUR 10.80 at Barclays

Downgrade	Kingfisher downgraded to Sell from Neutral at UBS » 05:15 08/12/22 08/12 05:15 08/12/22 05:15 KGFHY Kingfisher $6.32 / -0.095 (-1.48%) UBS analyst Saranja… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research KGFHY Kingfisher $6.32 / -0.095 (-1.48%) 08/03/22 Societe Generale Kingfisher downgraded to Sell from Hold at Societe Generale 07/05/22 Deutsche Bank Kingfisher price target lowered to EUR 305 from EUR 335 at Deutsche Bank 05/25/22 JPMorgan Kingfisher price target lowered to 245 GBp from 255 GBp at JPMorgan 04/04/22 Deutsche Bank Kingfisher price target lowered to 335 GBp from 355 GBp at Deutsche Bank
Upgrade	Beazley upgraded to Overweight from Equal Weight at Morgan Stanley » 05:11 08/12/22 08/12 05:11 08/12/22 05:11 BZLYF Beazley $6.62 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research BZLYF Beazley $6.62 / + (+0.00%) 07/25/22 JPMorgan Beazley price target raised to 715 GBp from 690 GBp at JPMorgan 07/25/22 RBC Capital Beazley price target raised to 650 GBp from 575 GBp at RBC Capital 07/15/22 Credit Suisse Beazley price target raised to 540 GBp from 480 GBp at Credit Suisse 07/13/22 UBS Beazley downgraded to Neutral from Buy at UBS
Downgrade	ProQR Therapeutics downgraded to Neutral from Buy at Chardan » 05:08 08/12/22 08/12 05:08 08/12/22 05:08 PRQR ProQR Therapeutics / + Chardan analyst Keay… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PRQR ProQR Therapeutics / + 08/11/22 ProQR Therapeutics to focus exclusive on Axiomer RNA-editing platform 08/04/22 ProQR Therapeutics expects cash to fund operations into 2025 06/01/22 ProQR Therapeutics provides leadership updates 04/13/22 ProQR Therapeutics announces additional sepofarsen Illuminate trial analyses PRQR ProQR Therapeutics / + 08/11/22 Raymond James ProQR upgraded to Outperform at Raymond James on RNA editing 'conviction' 08/11/22 Raymond James ProQR Therapeutics upgraded to Outperform from Market Perform at Raymond James 05/12/22 Cantor Fitzgerald ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald 05/09/22 H.C. Wainwright ProQR Therapeutics price target lowered to $2 from $4 at H.C. Wainwright PRQR ProQR Therapeutics / + 08/04/22 ProQR Therapeutics reports Q2 EPS (EUR0.21) vs. (EUR0.24) last year 05/05/22 ProQR Therapeutics reports Q1 EPS (20c), consensus (25c) 02/24/22 ProQR Therapeutics reports Q4 EPS (EUR0.26) vs. (EUR0.26) last year
Conference/Events	OneSpan management to meet with BTIG » 04:55 08/12/22 08/12 04:55 08/12/22 04:55 OSPN OneSpan $11.26 / +0.07 (+0.63%) Security &… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events OSPN OneSpan $11.26 / +0.07 (+0.63%) 07/05/22 OneSpan appoints Michael Lillie as Chief Information Officer 06/13/22 OneSpan announces Lara Mataac as General Counsel and Chief Compliance Officer 05/23/22 OneSpan announces Michael Klieman as chief product officer 03/16/22 OneSpan appoints Eric Hanson as chief marketing officer OSPN OneSpan $11.26 / +0.07 (+0.63%) 02/23/22 DA Davidson OneSpan price target lowered to $23 from $32 at DA Davidson OSPN OneSpan $11.26 / +0.07 (+0.63%) 08/02/22 OneSpan reaffirms FY22 revenue guidance to meet or exceed FY21 revenue 08/02/22 OneSpan reports Q2 adjusted EPS (11c), consensus (9c) 05/03/22 OneSpan sees FY22 revenue to meet or exceed full year 2021 revenue 05/03/22 OneSpan reports Q1 adjusted EPS (1c), consensus (5c) 00:00 Today OneSpan
Conference/Events	JPMorgan retail analyst to hold analyst/industry conference call » 04:55 08/12/22 08/12 04:55 08/12/22 04:55 Retail/Broadlines &… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial

Events

Earnings calls, analyst events, roadshows and more

CAAS
Today at 08:00

China Automotive - CAAS Conference Calls
CASI
Today at 08:00

Casi Pharmaceuticals - CASI Conference Calls
GTEC
Today at 08:00

Greenland Technologies - GTEC Conference Calls
VERO
Today at 08:00

Venus Concept - VERO Conference Calls
EVK
Today at 08:00

Ever-Glory - EVK Conference Calls
CMMB
Today at 08:00

Chemomab Therapeutics - CMMB Conference Calls
HUMA
Today at 08:00

Humacyte - HUMA Conference Calls
Today at 08:30

Import Prices M/M: July 2022 Government Event
Today at 08:30

Import Prices Y/Y: July 2022 Government Event
Today at 08:30

Export Prices M/M: July 2022 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord Priced at: $0.43 21.5M Shares BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities Priced at: $1.50 13.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies Priced at: $215.00 3.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MIRM X MIRM Mirum Pharmaceuticals Spot Secondary Managers: JPMorgan, SVB Securities & Evercore ISI, Raymond James Priced at: $23.00 3.48M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TDW X TDW Tidewater Spot Secondary Managers: Morgan Stanley Priced at: $17.85 3.52M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	ATNX X ATNX Athenex Secondary Managers: SVB Securities Priced at: $.75 35.3M Shares CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler Priced at: $30.00 7.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVTC X EVTC Evertec Secondary Managers: JPMorgan Priced at: $32.00 6.26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LXU X LXU LSB Industries Secondary Managers: Goldman Sachs & UBS, Deutsche Bank, Jefferies, Piper Sandler, RBC Capital, BNP Paribas, Stifel Priced at: $13.00 13.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital Priced at: $14.00 8.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRNA X VRNA Verona Pharma Secondary Managers: Jefferies, Piper Sandler & Truist Priced at: $10.50 12.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNL X BNL Broadstone Net Lease Spot Secondary Managers: Goldman Sachs, BMO Capital, JPMorgan & Truist Priced at: $21.35 13M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Sandler & Stifel Priced at: $55.00 750K Shares MAIN X MAIN Main Street Spot Secondary Managers: RBC Capital, UBS & Wells Fargo Priced at: $42.85 1.17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity Priced at: $5.00 3M Shares REBN X REBN Reborn Coffee IPO Managers: EF Hutton Priced at: $5.00 1.44M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TGL X TGL Treasure Global IPO Managers: EF Hutton Priced at: $4.00 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler Priced at: $23.75 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	BIAF X BIAF Bioaffinity Technologies IPO Managers: WallachBeth $6.00-6.25 1.285M Shares
Wed	No deals
Thurs	CERE X CERE Cerevel Therapeutics Secondary Managers: Morgan Stanley, Goldman Sachs, Jefferies & Evercore ISI, Loop Capital, Seibert Williams $41.42 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RANI X RANI Rani Therapeutics Secondary Managers: BofA, Cantor Fitzgerald & UBS, BTIG, H.C. Wainwright $11.11 CERT X CERT Certara Spot Secondary Managers: Morgan Stanley $17.75-18.50 7M Shares INSP X INSP Inspire Medical Spot Secondary Managers: Goldman Sachs $215.00-222.46 1M Shares
Fri	No deals

View All Syndicate Announcements »

Genesco appoints Gregory Sandfort as lead independent director

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access